Prevalence of and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand
- PMID: 21075913
- DOI: 10.1177/1545109710373832
Prevalence of and risk factors for pre-diabetes in HIV-1-infected patients in Bangkok, Thailand
Abstract
Pre-diabetes substantially increases the risk of developing macrovascular complication and progression to diabetes. This study aimed to determine the prevalence of and risk factors for pre-diabetes in HIV-1-infected patients. A cross-sectional study was conducted in HIV-1-infected patients who visited the infectious diseases clinic in a university hospital. Fasting plasma glucose (FPG) was performed. There were 149 patients, mean age 42.2 years, and 65.1% were males. Median CD4 count was 434 cells/mm(3). In total, 92% have received antiretroviral therapy (ART), with a median duration of 0.8 years. The prevalence of pre-diabetes was 27.5%. From multivariate analysis, body weight ([BW] per 5 kg increase, odds ratio [OR] = 1.241; 95% confidence interval [CI], 1.014-1.518; P = .036) and, tentatively, male gender (OR = 2.906; 95% CI, 0.941-8.976; P = .064) were risk factors for pre-diabetes. Nevirapine (NVP) use (OR = 0.383; 95% CI, 0.161-0.910; P = .030) was a protective factor for pre-diabetes. Pre-diabetes is common in HIV-1-infected patients receiving ART. Screening for pre-diabetes and active management should be performed in patients with risk factors.
Similar articles
-
Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.Clin Ther. 2007 Jul;29(7):1448-55. doi: 10.1016/j.clinthera.2007.07.025. Clin Ther. 2007. PMID: 17825696
-
Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.J Clin Virol. 2008 Apr;41(4):310-3. doi: 10.1016/j.jcv.2007.12.015. Epub 2008 Mar 7. J Clin Virol. 2008. PMID: 18316243
-
Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.Clin Infect Dis. 2008 Jul 15;47(2):250-7. doi: 10.1086/589294. Clin Infect Dis. 2008. PMID: 18532884
-
Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.J Med Assoc Thai. 2008 Feb;91(2):159-65. J Med Assoc Thai. 2008. PMID: 18389979
-
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.BMC Infect Dis. 2005 Aug 24;5:67. doi: 10.1186/1471-2334-5-67. BMC Infect Dis. 2005. PMID: 16120209 Free PMC article.
Cited by
-
Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors.Biomed Res Int. 2017;2017:7481597. doi: 10.1155/2017/7481597. Epub 2017 Feb 15. Biomed Res Int. 2017. PMID: 28293638 Free PMC article.
-
Effects of an intensive lifestyle intervention and the role of sleep in people living with HIV and prediabetes: a pilot and feasibility study.BMC Res Notes. 2021 Apr 17;14(1):145. doi: 10.1186/s13104-021-05558-z. BMC Res Notes. 2021. PMID: 33865450 Free PMC article.
-
Metabolic abnormalities in adult HIV infected population on antiretroviral medication in Malaysia: a cross-sectional survey.BMC Public Health. 2013 Aug 15;13:758. doi: 10.1186/1471-2458-13-758. BMC Public Health. 2013. PMID: 23947428 Free PMC article.
-
Diabetes and HIV: current understanding and future perspectives.Curr Diab Rep. 2013 Jun;13(3):419-27. doi: 10.1007/s11892-013-0369-9. Curr Diab Rep. 2013. PMID: 23446780 Review.
-
Association between gut microbiota and prediabetes in people living with HIV.Curr Res Microb Sci. 2022 May 31;3:100143. doi: 10.1016/j.crmicr.2022.100143. eCollection 2022. Curr Res Microb Sci. 2022. PMID: 35909623 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials